miércoles, 30 de octubre de 2019

Tumor immune microenvironment and immunotherapy

Tumor immune microenvironment and immunotherapy

Tumor immune microenvironment and immunotherapy

Guest Editors: Zlatko Trajanoski and Noel de Miranda

New Content ItemCancer treatment has been revolutionized by recent unraveling and targeting of the interaction between tumors and the host immune system. Genome Medicine is pleased to announce a special issue on ‘Tumor immune microenvironment and immunotherapy’, guest edited by Zlatko Trajanoski of Medical University of Innsbruck and Noel de Miranda of Leiden University Medical Center. The issue captures recent insights using genomic approaches toward characterizing the immune system in the tumor microenvironment, immunotherapeutic targeting, as well as functional – and dysfunctional – anti-tumor immune responses, highlighting the clinical applications of these advances.
This collection of articles has not been sponsored and articles have undergone the journal’s standard peer-review process. The Guest Editors declare that they have no competing interests.  Guest Editors serve an advisory role to guide the scope of the special issue and commissioned content; final editorial decisions lie with the Editor.
  1. Content type:Review

    Neoantigens are newly formed peptides created from somatic mutations that are capable of inducing tumor-specific T cell recognition. Recently, researchers and clinicians have leveraged next generation sequenci...
    Authors:Megan M. Richters, Huiming Xia, Katie M. Campbell, William E. Gillanders, Obi L. Griffith and Malachi Griffith
    Citation:Genome Medicine 2019 11:56
    Published on: 
  2. Content type:Research

    Neoantigens that arise as a consequence of tumor-specific mutations can be recognized by T lymphocytes leading to effective immune surveillance. In colorectal cancer (CRC) and other tumor types, a high number ...
    Authors:Giuseppe Rospo, Annalisa Lorenzato, Nabil Amirouchene-Angelozzi, Alessandro Magrì, Carlotta Cancelliere, Giorgio Corti, Carola Negrino, Vito Amodio, Monica Montone, Alice Bartolini, Ludovic Barault, Luca Novara, Claudio Isella, Enzo Medico, Andrea Bertotti, Livio Trusolino…
    Citation:Genome Medicine 2019 11:42
    Published on: 
  3. Content type:Opinion

    The expression of antigens that are recognized by self-reactive T cells is essential for immune-mediated tumor rejection by immune checkpoint blockade (ICB) therapy. Growing evidence suggests that mutation-ass...
    Authors:Claire Lhuillier, Nils-Petter Rudqvist, Olivier Elemento, Silvia C. Formenti and Sandra Demaria
    Citation:Genome Medicine 2019 11:40
    Published on: 
  4. Content type:Comment

    Personalized care of cancer patients undergoing treatment with immune checkpoint inhibitors will require approaches that can predict their susceptibility to immune-related adverse events. Understanding the rol...
    Authors:Zia Khan, Christian Hammer, Ellie Guardino, G. Scott Chandler and Matthew L. Albert
    Citation:Genome Medicine 2019 11:39
    Published on: 
  5. Content type:Method

    We introduce quanTIseq, a method to quantify the fractions of ten immune cell types from bulk RNA-sequencing data. quanTIseq was extensively validated in blood and tumor samples using simulated, flow cytometry...
    Authors:Francesca Finotello, Clemens Mayer, Christina Plattner, Gerhard Laschober, Dietmar Rieder, Hubert Hackl, Anne Krogsdam, Zuzana Loncova, Wilfried Posch, Doris Wilflingseder, Sieghart Sopper, Marieke Ijsselsteijn, Thomas P. Brouwer, Douglas Johnson, Yaomin Xu, Yu Wang…
    Citation:Genome Medicine 2019 11:34
    Published on: 
    The Correction to this article has been published in Genome Medicine 2019 11:50
  6. Content type:Comment

    The nature of the tumor antigens that are detectable by T cells remains unclear. In melanoma, T cells were shown to react against major histocompatibility complex (MHC)-associated peptides (MAPs) that are deri...
    Authors:Grégory Ehx and Claude Perreault
    Citation:Genome Medicine 2019 11:29
    Published on: 
    The Research to this article has been published in Genome Medicine 2019 11:28
  7. Content type:Research

    Although mutated HLA ligands are considered ideal cancer-specific immunotherapy targets, evidence for their presentation is lacking in hepatocellular carcinomas (HCCs). Employing a unique multi-omics approach ...
    Authors:Markus W. Löffler, Christopher Mohr, Leon Bichmann, Lena Katharina Freudenmann, Mathias Walzer, Christopher M. Schroeder, Nico Trautwein, Franz J. Hilke, Raphael S. Zinser, Lena Mühlenbruch, Daniel J. Kowalewski, Heiko Schuster, Marc Sturm, Jakob Matthes, Olaf Riess, Stefan Czemmel…
    Citation:Genome Medicine 2019 11:28
    Published on: 
    The Comment to this article has been published in Genome Medicine 2019 11:29

No hay comentarios:

Publicar un comentario